Katherine Clifton

1.2k total citations
41 papers, 398 citations indexed

About

Katherine Clifton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Katherine Clifton has authored 41 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Katherine Clifton's work include Advanced Breast Cancer Therapies (20 papers), Cancer Genomics and Diagnostics (17 papers) and Breast Cancer Treatment Studies (7 papers). Katherine Clifton is often cited by papers focused on Advanced Breast Cancer Therapies (20 papers), Cancer Genomics and Diagnostics (17 papers) and Breast Cancer Treatment Studies (7 papers). Katherine Clifton collaborates with scholars based in United States, Italy and Brazil. Katherine Clifton's co-authors include X. Cynthia, Lindsay L. Peterson, Luigi Fontana, Jennifer K. Litton, Gabriel N. Hortobágyi, Amanda Parkes, Carla L. Warneke, Oluchi Oke, Meghan Karuturi and Foluso O. Ademuyiwa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Katherine Clifton

35 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine Clifton United States 10 194 113 106 80 79 41 398
Toshiaki Iwase United States 13 282 1.5× 97 0.9× 114 1.1× 92 1.1× 133 1.7× 35 439
Lorenzo Rossi Switzerland 10 192 1.0× 110 1.0× 99 0.9× 90 1.1× 25 0.3× 30 402
Christian Focan Belgium 8 323 1.7× 130 1.2× 73 0.7× 48 0.6× 57 0.7× 10 535
Riccardo Lobefaro Italy 11 265 1.4× 112 1.0× 140 1.3× 131 1.6× 87 1.1× 31 494
Jing Cheng China 13 118 0.6× 121 1.1× 115 1.1× 134 1.7× 16 0.2× 39 402
Sara Junius Belgium 6 233 1.2× 144 1.3× 62 0.6× 109 1.4× 25 0.3× 8 475
Ana Elisa Lohmann Canada 11 240 1.2× 57 0.5× 92 0.9× 167 2.1× 70 0.9× 27 397
Jean‐Pierre Bleuse France 11 309 1.6× 63 0.6× 125 1.2× 84 1.1× 41 0.5× 21 468
Utku Oflazoğlu Türkiye 11 154 0.8× 44 0.4× 45 0.4× 58 0.7× 73 0.9× 41 312
Т. Yu. Semiglazova Russia 7 237 1.2× 79 0.7× 71 0.7× 57 0.7× 15 0.2× 140 367

Countries citing papers authored by Katherine Clifton

Since Specialization
Citations

This map shows the geographic impact of Katherine Clifton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Clifton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Clifton more than expected).

Fields of papers citing papers by Katherine Clifton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Clifton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Clifton. The network helps show where Katherine Clifton may publish in the future.

Co-authorship network of co-authors of Katherine Clifton

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Clifton. A scholar is included among the top collaborators of Katherine Clifton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Clifton. Katherine Clifton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Medford, Arielle J., Yuval Gefen, Andrzej Niemierko, et al.. (2025). Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes. Breast Cancer Research and Treatment. 212(3). 437–447.
2.
Gerratana, Lorenzo, Arielle J. Medford, Katherine Clifton, et al.. (2025). Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer. JAMA Network Open. 8(2). e2461899–e2461899. 4 indexed citations
3.
Ademuyiwa, Foluso O., X. Cynthia, Katherine N. Weilbaecher, et al.. (2025). Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 31(11). 2173–2182. 1 indexed citations
4.
5.
6.
Wang, Ming, Laura Testa, Renata Colombo Bonadio, et al.. (2024). Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer. JCO Oncology Practice. 21(6). 832–842. 2 indexed citations
7.
Gerratana, Lorenzo, Andrew A. Davis, Carolina Reduzzi, et al.. (2024). Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling. Cancer Letters. 609. 217325–217325. 13 indexed citations
8.
Gerratana, Lorenzo, Andrew A. Davis, Carolina Reduzzi, et al.. (2023). Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precision Oncology. 7(7). e2200531–e2200531. 7 indexed citations
9.
Gerratana, Lorenzo, Katherine Clifton, Arielle J. Medford, et al.. (2023). Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. Clinical Cancer Research. 29(16). 3092–3100. 4 indexed citations
10.
Hurvitz, Sara A., Erika Hamilton, Alexander I. Spira, et al.. (2023). A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS1114–TPS1114. 15 indexed citations
11.
12.
13.
Krishnamurthy, Jairam, Jingqin Luo, Rama Suresh, et al.. (2022). A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. npj Breast Cancer. 8(1). 35–35. 5 indexed citations
14.
Clifton, Katherine, et al.. (2022). Loneliness, social isolation, and social support in older adults with active cancer during the COVID-19 pandemic. Journal of Geriatric Oncology. 13(8). 1122–1131. 19 indexed citations
15.
Clifton, Katherine, X. Cynthia, Luigi Fontana, & Lindsay L. Peterson. (2021). Intermittent fasting in the prevention and treatment of cancer. CA A Cancer Journal for Clinicians. 71(6). 527–546. 109 indexed citations
16.
Clifton, Katherine, Jingqin Luo, Tao Yu, et al.. (2020). Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). Breast Cancer Research and Treatment. 185(3). 639–646. 3 indexed citations
17.
Clifton, Katherine, et al.. (2019). Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Research and Treatment. 175(3). 667–674. 25 indexed citations
18.
Clifton, Katherine, et al.. (2018). Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. The Breast Journal. 24(4). 691–692. 8 indexed citations
19.
Clifton, Katherine, Angelica M. Gutierrez‐Barrera, Junsheng Ma, et al.. (2018). Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Research and Treatment. 170(1). 101–109. 18 indexed citations
20.
Parkes, Amanda, Katherine Clifton, Oluchi Oke, et al.. (2018). Characterization of bone only metastasis patients with respect to tumor subtypes. npj Breast Cancer. 4(1). 2–2. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiaki Iwase Breakdown of academic impact, for papers by Lorenzo Rossi Breakdown of academic impact, for papers by Christian Focan Breakdown of academic impact, for papers by Riccardo Lobefaro Breakdown of academic impact, for papers by Jing Cheng Breakdown of academic impact, for papers by Sara Junius Breakdown of academic impact, for papers by Ana Elisa Lohmann Breakdown of academic impact, for papers by Jean‐Pierre Bleuse Breakdown of academic impact, for papers by Utku Oflazoğlu Breakdown of academic impact, for papers by Т. Yu. Semiglazova
Rankless by CCL
2026